Vitamin B₃ Supplementation for Optic Neuropathies: A Comprehensive Review.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2024-03-01 Epub Date: 2023-12-27 DOI:10.1089/jop.2023.0125

Júlio Almeida, Tomás R Costa, Maria Vivas, Catarina Monteiro, Fernando T Vaz, Quirina Ferreira, Isabel Prieto, Luís A Pinto, Joana T Ferreira

{"title":"Vitamin B3 Supplementation for Optic Neuropathies: A Comprehensive Review.","authors":"Júlio Almeida, Tomás R Costa, Maria Vivas, Catarina Monteiro, Fernando T Vaz, Quirina Ferreira, Isabel Prieto, Luís A Pinto, Joana T Ferreira","doi":"10.1089/jop.2023.0125","DOIUrl":null,"url":null,"abstract":"Optic neuropathies, such as glaucoma, are some of the leading causes of irreversible blindness worldwide. There has been a lot of research for potential therapies that could attenuate and even reduce the impact of the pathological pathways that lead to the loss of retinal ganglion cells (RGCs). In recent years, vitamin B3 (nicotinamide) has gained some interest as a viable option for these neurodegenerative diseases due to its fundamental role in enhancing the mitochondria metabolism of the RGCs. This review focuses on elucidating the impact of vitamin B3 on retinal cells, especially when in a dysfunctional state like what happens in optic neuropathies, especially glaucoma. This review also summarizes the existing and future research on the clinical effects of vitamin B3 in these optic neuropathies, and determines appropriate recommendations regarding its dosing, efficacy, and eventual side effects.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"111-116"},"PeriodicalIF":1.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2023.0125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Optic neuropathies, such as glaucoma, are some of the leading causes of irreversible blindness worldwide. There has been a lot of research for potential therapies that could attenuate and even reduce the impact of the pathological pathways that lead to the loss of retinal ganglion cells (RGCs). In recent years, vitamin B₃ (nicotinamide) has gained some interest as a viable option for these neurodegenerative diseases due to its fundamental role in enhancing the mitochondria metabolism of the RGCs. This review focuses on elucidating the impact of vitamin B₃ on retinal cells, especially when in a dysfunctional state like what happens in optic neuropathies, especially glaucoma. This review also summarizes the existing and future research on the clinical effects of vitamin B₃ in these optic neuropathies, and determines appropriate recommendations regarding its dosing, efficacy, and eventual side effects.

查看原文本刊更多论文

补充维生素 B3 治疗视神经病变：全面回顾。

视神经病变（如青光眼）是导致全球不可逆失明的主要原因之一。人们一直在研究能够减轻甚至减少导致视网膜神经节细胞（RGC）丧失的病理途径影响的潜在疗法。近年来，维生素 B3（烟酰胺）因其在增强 RGC 线粒体新陈代谢中的基本作用而作为治疗这些神经退行性疾病的可行方案受到了一些关注。本综述侧重于阐明维生素 B3 对视网膜细胞的影响，尤其是在视神经病变（特别是青光眼）等功能失调的情况下。本综述还总结了有关维生素 B3 在这些视神经病变中的临床效果的现有和未来研究，并确定了有关其剂量、疗效和最终副作用的适当建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ocular Pharmacology and Therapeutics 医学-眼科学

CiteScore

4.60

自引率

4.30%

发文量

审稿时长

1 months

期刊介绍： Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.